Adimab signed its first-ever technology transfer and license agreement that gives a partner broad access to the Lebanon, New Hampshire-based company's antibody discovery platform with GlaxoSmithKline and immediately followed the first deal with a second, expanding Adimab's existing relationship with Biogen Idec.
Adimab turns profit on deals with GSK, Biogen
Adimab signed its first-ever technology transfer and license agreement that gives a partner broad access to the Lebanon, New Hampshire-based company's antibody discovery platform with GlaxoSmithKline and immediately followed the first deal with a second, expanding Adimab's existing relationship with Biogen Idec.
More from Archive
More from Scrip
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.